Octreotide long-term treatment in patients with portal hypertension: persistent inhibition of postprandial glucagon response without major changes in renal function

1997 ◽  
Vol 26 (4) ◽  
pp. 816-825 ◽  
Author(s):  
Alberto Malesci ◽  
Milena Tacconi ◽  
Angela Valentini ◽  
Mauro Basilico ◽  
Elettra Lorenzano ◽  
...  
Keyword(s):  
Renal Function ◽  
Portal Hypertension ◽  
Term Treatment ◽  
Long Term Treatment

Long-Term Treatment with Pivmecillinam in Patients with Recurrent Bacteriuria

1982 ◽  
Vol 10 (3) ◽  
pp. 179-182
Author(s):  
B Bresky ◽  
K Lincoln
Keyword(s):  
Escherichia Coli ◽  
Adverse Effect ◽  
Renal Function ◽  
Term Treatment ◽  
The Body ◽  
End Of Treatment ◽  
Long Term Treatment ◽  
Tract Infections

Thirty out-patients with chronic recurrent urinary tract infections, who had failed to respond to 10 days treatment with either pivmecillinam and/or amoxycillin, received a 3-month course of pivmecillinam at a dose of 200 mg, three times daily. Twenty-seven patients had bacteriuria due to Enterobacteriaceae, mainly Escherichia coli, sensitive to mecillinam in vitro. Pivmecillinam eradicated all the initial urinary pathogens. Reinfections occurred during treatment in three patients, who remained asymptomatic. Four subjects complained of gastro-intestinal side-effects, and therapy was withdrawn in three instances. Another three patients described unusual adverse events towards the end of the course of treatment, described as an odd sensation in the body and a desire for salt. The sensation disappeared a few days after the end of treatment. Treatment with pivmecillinam had no adverse effect on haematopoietic, hepatic or renal function.

Aluminium Bone Deposits in Normal Renal Function Patients after Long-Term Treatment by Plasma Exchange

1989 ◽  
Vol 12 (10) ◽  
pp. 664-667 ◽  
Author(s):  
C. Mousson ◽  
S.A. Charhon ◽  
M. Ammar ◽  
M. Accominotti ◽  
G. Rifle
Keyword(s):  
Renal Function ◽  
Bone Formation ◽  
Plasma Exchange ◽  
Normal Renal Function ◽  
Bone Biopsy ◽  
Term Treatment ◽  
Normal Range ◽  
Non Invasive ◽  
Long Term Treatment

The accumulation of aluminium (AI) can cause AI bone deposits, osteomalacia and encephalopathy. As albumin solutions used as replacement fluid in plasma exchange (PE) are contaminated with AI, we studied AI overload in two symptomless patients with normal renal function, treated by long-term plasma exchange (PE). Total AI loading was calculated at 1750 μmol in patient 1 (178 PE sessions) and 2100 μmol in patient 2 (153 PE sessions). Bone biopsy showed AI deposits and low bone formation without osteomalacia in patient 1 and only osteoporosis in patient 2. Plasma AI levels were useless in detecting early AI overload, because the remained in the normal range, even after PE in both patients. Bone biopsy was the best means of recognizing AI intoxication, but cannot be recommended for frequent evaluations. However, the desferrioxamine mobilization test can be proposed as a repetitive non-invasive investigation method.

The effect of nisoldipine on renal function in the long-term treatment of hypertension in patients with and without renal impairment

1989 ◽  
Vol 37 (5) ◽  
pp. 437-441 ◽  
Author(s):  
J. Wilson ◽  
M. M. A. E. Wahbha ◽  
P. G. Martin ◽  
R. Hainsworth ◽  
A. M. Brownjohn ◽  
...  
Keyword(s):  
Renal Function ◽  
Renal Impairment ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Treatment Of Hypertension

scholarly journals Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate

2021 ◽  
Author(s):  
Kensuke Abe ◽  
Taku Obara ◽  
Satomi Kamio ◽  
Asahi Kondo ◽  
Junji Imamura ◽  
...  
Keyword(s):  
Renal Function ◽  
Renal Dysfunction ◽  
Tenofovir Disoproxil Fumarate ◽  
Antiviral Effect ◽  
Term Treatment ◽  
Long Term Treatment ◽  
The Difference ◽  
Tenofovir Alafenamide ◽  
Hiv 1

Abstract BACKGROUND Tenofovir disoproxil fumarate (TDF) has a strong antiviral effect, but TDF is known to cause renal dysfunction. Therefore, we are investigating preventing renal dysfunction by replacing TDF with tenofovir alafenamide fumarate (TAF), which is known to be relatively safe to the kidneys. However, the changes in renal function under long-term use of TAF are not known. In this study, we evaluated renal function in Japanese HIV-1-positive patients switching to TAF after long-term treatment with TDF.METHODS A single-center observational study was conducted in Japanese HIV-1-positive patients. TDF was switched to TAF after at least 48 weeks of treatment so we could evaluate the long-term use of TDF. The primary endpoint was the estimated glomerular filtration rate (eGFR) at 144 weeks of TAF administration. In addition, we predicted the factors that would lead to changes in eGFR after long-term use of TAF.RESULTS Of the 125 HIV-1-positive patients who were prescribed TAF at our hospital during the study period, 70 fulfilled the study criteria. The eGFR at the time of switching from TDF to TAF was 81.4 ± 21.1 mL/min/1.73 m2. eGFR improved significantly after 12 weeks of taking TAF but significantly decreased at 96 and 144 weeks. At 144 weeks of taking TAF, the factors significantly correlated with the difference in eGFR from baseline were the difference in eGFR at 48 weeks of taking TAF and age at the start of TAF.CONCLUSIONS In this study, Japanese HIV-1-positive patients who had been taking TDF for a long period of time showed a decrease in eGFR after switching to long-term use of TAF. Japanese HIV-1-positive patients are expected to take TAF for a long time. Depending on age, laboratory values related to renal function need to be monitored carefully.

Sign in / Sign up

Export Citation Format

Share Document